XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements, Assets and Liabilities are Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Mar. 31, 2023
Assets: [Abstract]    
Investment $ 239,927 $ 304,317
Earn-Out Shares [Member]    
Recurring Fair Value Measurements [Abstract]    
Non financial liabilities at fair value 24,900 15,200
Private Placement Warrants [Member]    
Recurring Fair Value Measurements [Abstract]    
Non financial liabilities at fair value   15,200
Arbutus Biopharma Corporation [Member]    
Assets: [Abstract]    
Investment 97,100 117,700
Level 1 [Member] | Warrant [Member] | Public Warrants [Member]    
Recurring Fair Value Measurements [Abstract]    
Financial liabilities at fair value   29,900
Level 3 [Member] | Earn-Out Shares [Member]    
Recurring Fair Value Measurements [Abstract]    
Non financial liabilities at fair value 24,900 15,200
Level 3 [Member] | Warrant [Member] | Private Placement Warrants [Member]    
Recurring Fair Value Measurements [Abstract]    
Financial liabilities at fair value   15,200
Level 3 [Member] | Other Liability Instruments Measured At Fair Value Measurement [Member]    
Recurring Fair Value Measurements [Abstract]    
Other Liability instruments measured at fair value measurement 3,500 3,300
Recurring [Member]    
Assets: [Abstract]    
Total assets at fair value 6,753,863 1,801,043
Liabilities: [Abstract]    
Debt issued by Dermavant to NovaQuest 221,510 207,640
Liability instruments measured at fair value [1] 28,374 63,546
Total liabilities at fair value 249,884 271,186
Recurring [Member] | Money Market Funds [Member]    
Assets: [Abstract]    
Money market funds 6,513,936 1,496,726
Recurring [Member] | Common Shares [Member] | Datavant [Member]    
Assets: [Abstract]    
Investment 135,934 178,579
Recurring [Member] | Common Shares [Member] | Arbutus Biopharma Corporation [Member]    
Assets: [Abstract]    
Investment 97,119 117,708
Recurring [Member] | Other Investments [Member]    
Assets: [Abstract]    
Investment 6,874 8,030
Recurring [Member] | Level 1 [Member]    
Assets: [Abstract]    
Total assets at fair value 6,617,929 1,622,464
Liabilities: [Abstract]    
Debt issued by Dermavant to NovaQuest 0 0
Liability instruments measured at fair value [1] 0 29,895
Total liabilities at fair value 0 29,895
Recurring [Member] | Level 1 [Member] | Money Market Funds [Member]    
Assets: [Abstract]    
Money market funds 6,513,936 1,496,726
Recurring [Member] | Level 1 [Member] | Common Shares [Member] | Datavant [Member]    
Assets: [Abstract]    
Investment 0 0
Recurring [Member] | Level 1 [Member] | Common Shares [Member] | Arbutus Biopharma Corporation [Member]    
Assets: [Abstract]    
Investment 97,119 117,708
Recurring [Member] | Level 1 [Member] | Other Investments [Member]    
Assets: [Abstract]    
Investment 6,874 8,030
Recurring [Member] | Level 2 [Member]    
Assets: [Abstract]    
Total assets at fair value 0 0
Liabilities: [Abstract]    
Debt issued by Dermavant to NovaQuest 0 0
Liability instruments measured at fair value [1] 0 0
Total liabilities at fair value 0 0
Recurring [Member] | Level 2 [Member] | Money Market Funds [Member]    
Assets: [Abstract]    
Money market funds 0 0
Recurring [Member] | Level 2 [Member] | Common Shares [Member] | Datavant [Member]    
Assets: [Abstract]    
Investment 0 0
Recurring [Member] | Level 2 [Member] | Common Shares [Member] | Arbutus Biopharma Corporation [Member]    
Assets: [Abstract]    
Investment 0 0
Recurring [Member] | Level 2 [Member] | Other Investments [Member]    
Assets: [Abstract]    
Investment 0 0
Recurring [Member] | Level 3 [Member]    
Assets: [Abstract]    
Total assets at fair value 135,934 178,579
Liabilities: [Abstract]    
Debt issued by Dermavant to NovaQuest 221,510 207,640
Liability instruments measured at fair value [1] 28,374 33,651
Total liabilities at fair value 249,884 241,291
Recurring [Member] | Level 3 [Member] | Money Market Funds [Member]    
Assets: [Abstract]    
Money market funds 0 0
Recurring [Member] | Level 3 [Member] | Common Shares [Member] | Datavant [Member]    
Assets: [Abstract]    
Investment 135,934 178,579
Recurring [Member] | Level 3 [Member] | Common Shares [Member] | Arbutus Biopharma Corporation [Member]    
Assets: [Abstract]    
Investment 0 0
Recurring [Member] | Level 3 [Member] | Other Investments [Member]    
Assets: [Abstract]    
Investment $ 0 $ 0
[1] At December 31, 2023, Level 3 includes the fair value of the Earn-Out Shares of $24.9 million and other liability instruments issued of $3.5 million. At March 31, 2023, Level 1 includes the fair value of the Public Warrants of $29.9 million, and Level 3 includes the fair value of the Earn-Out Shares of $15.2 million, Private Placement Warrants of $15.2 million, and other liability instruments issued of $3.3 million.